axumin
blue earth diagnostics ireland ltd - fluciclovine (18f) - prostatic neoplasms; radionuclide imaging - diagnostyczne radiofarmaceutyki - ten produkt leczniczy jest przeznaczony wyłącznie do celów diagnostycznych. axumin jest wskazany do pozytonowej tomografii emisyjnej (pet), tomografia komputerowa w celu wykrycia nawrotu raka gruczołu krokowego u dorosłych mężczyzn z podejrzeniem nawrotu na podstawie podwyższonego ciśnienia poziomy antygenu specyficznego dla prostaty (psa) po pierwotnym leczeniu.
gamma anty-d 150 150 mcg/ml roztwór do wstrzykiwań
synthaverse s.a. - immunoglobulinum humanum anti-d - roztwór do wstrzykiwań - 150 mcg/ml
gamma anty-d 50 50 mcg/ml roztwór do wstrzykiwań
synthaverse s.a. - immunoglobulinum humanum anti-d - roztwór do wstrzykiwań - 50 mcg/ml
rhophylac 300 300 mcg/2 ml (1500 iu) roztwór do wstrzykiwań
csl behring gmbh - immunoglobulinum humanum anti-d - roztwór do wstrzykiwań - 300 mcg/2 ml (1500 iu)
rhesonativ 625 iu/ml (125 mcg) roztwór do wstrzykiwań
octapharma (ip) sprl - immunoglobulinum humanum anti-d - roztwór do wstrzykiwań - 625 iu/ml (125 mcg)
finiprost 5 mg tabletki powlekane
aurobindo pharma (malta) limited - finasteridum - tabletki powlekane - 5 mg
rhesonativ 750 iu/ml roztwór do wstrzykiwań
octapharma (ip) sprl - immunoglobulinum humanum anti-d - roztwór do wstrzykiwań - 750 iu/ml
dutrys 0,5 mg kapsułki miękkie
krka, d.d., novo mesto - dutasteridum - kapsułki miękkie - 0,5 mg
rinvoq
abbvie deutschland gmbh & co. kg - upadacitinib - zapalenie stawów, reumatoidalne - leki immunosupresyjne - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.
blenrep
glaxosmithkline (ireland) limited - belantamab mafodotin - szpiczak mnogi - Środki przeciwnowotworowe - blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-cd38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.